leisure time -WSS

leisure time

author：explore 2025-09-27 18:53:42 - browse：22348

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

hotspot

WSS

Glen Campbell's doctor discusses his public struggle with Alzheimer's

A letter from the executive editor: The 2023 STATUS List

Criminal prosecution for violating HIPAA: an emerging threat

Helping hospitals and community health centers plan for resilience

Helping hospitals and community health centers plan for resilience

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

knowledge

leisure time

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Hollywood unions extend contract negotiations for actors

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Supreme Court strikes down use of affirmative action

'Screen and refer' systems are hurting patients

Medical records are filled with copy

HIV vaccine remains elusive. Immunologists keep trying new ideas

Jerome Adams on the need for new antivirals for Covid

Case highlights the risks of experimental stem cell therapy

knowledge

What affirmative action's end means to a medical student

Vertex cell therapy lets patients with type 1 diabetes stop insulin

It's time to retire 'poor historian' from clinicians' vocabularies

Use doctors trained outside the U.S. to ease the physician shortage

Data integrity in scientific journals requires "effort" by publishers, institutions

When prostate cancer spreads, where it goes matters

hotspot

knowledge

focus

hotspot